BioCryst Pharmaceuticals Inc (BCRX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:BioCryst Pharmaceuticals Inc (BCRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012286
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BioCryst Pharmaceuticals Inc (BioCryst) designs, optimizes and develops small molecule drugs that block key enzymes in the pathogenesis of diseases. The company focuses on the treatment of rare diseases and develops drugs for infectious diseases and hereditary Angioedemaon. Biocryst integrates disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. The company’s products include peramivir injections Rapivab, Alpivab, Rapiacta and Peramiflu for the treatment of Influenza. The company has strategic partnerships with corporate and academic institutes. It has two wholly owned subsidiaries JPR Royalty Sub LLC and MDCP LLC. BioCryst has research operations in Birmingham, Alabama and is headquartered in Durham, North Carolina, the US.

BioCryst Pharmaceuticals Inc (BCRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
BioCryst Pharma Enters into Licensing Agreement with Seqirus 11
Equity Offering 13
BioCryst Pharma Plans to Raise up to USD200 Million in Public Offering of Securities 13
BioCryst Pharma Raises USD92 Million in Public Offering of Shares 14
BioCryst Pharma Files Registration Statement to Raise Funds through Public Offering of Shares 16
BioCryst Pharma Prices Public Offering of Shares for USD45 Million 17
BioCryst Pharma Raises USD115 Million in Public Offering of Shares 19
BioCryst Pharma Completes Public Offering Of Shares For US$20.3 Million 21
Debt Offering 23
BioCryst Pharma Completes Private Placement Of Senior Secured Notes Due 2020 For US$30 Million 23
BioCryst Pharmaceuticals Inc – Key Competitors 24
BioCryst Pharmaceuticals Inc – Key Employees 25
BioCryst Pharmaceuticals Inc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Nov 07, 2017: BioCryst Reports Third Quarter 2017 Financial Results 27
Aug 07, 2017: BioCryst Reports Second Quarter 2017 Financial Results 29
May 04, 2017: BioCryst Reports First Quarter 2017 Financial Results 31
Feb 27, 2017: BioCryst Reports Fourth Quarter and Full Year 2016 Financial Results 33
Nov 07, 2016: BioCryst Reports Third Quarter 2016 Financial Results 35
Aug 04, 2016: BioCryst Reports Second Quarter 2016 Financial Results 37
May 05, 2016: BioCryst Reports First Quarter 2016 Financial Results 39
Feb 23, 2016: BioCryst Reports Fourth Quarter & Full Year 2015 Financial Results 40
Corporate Communications 42
May 30, 2017: Robert A. Ingram Named Chairman of BioCryst Pharmaceuticals 42
Product News 43
10/26/2016: BioCryst Announces Late Breaker Presentation of Galidesivir (BCX4430) Nonclinical Results in Zika Virus Infection at IDWeek 2016 43
06/05/2017: BioCryst Announces RAPIVAB Pediatric sNDA Acceptance 44
Product Approvals 45
Jan 30, 2017: BioCryst Announces the Acceptance of Peramivir MAA Filing by the European Medicines Agency 45
Jan 08, 2017: BioCryst Receives Health Canada Approval for RAPIVAB for the Treatment of Influenza 46
Clinical Trials 47
Sep 07, 2016: BioCryst Announces Positive Study Results for BCX4430 Delayed Treatment of Ebola Virus Infection in a Non-Human Primate Model 47
Mar 07, 2016: Study Results From Zika Virus Infected Mice Treated With BCX4430 to be Presented at WHO Conference 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
BioCryst Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
BioCryst Pharma Enters into Licensing Agreement with Seqirus 11
BioCryst Pharma Plans to Raise up to USD200 Million in Public Offering of Securities 13
BioCryst Pharma Raises USD92 Million in Public Offering of Shares 14
BioCryst Pharma Files Registration Statement to Raise Funds through Public Offering of Shares 16
BioCryst Pharma Prices Public Offering of Shares for USD45 Million 17
BioCryst Pharma Raises USD115 Million in Public Offering of Shares 19
BioCryst Pharma Completes Public Offering Of Shares For US$20.3 Million 21
BioCryst Pharma Completes Private Placement Of Senior Secured Notes Due 2020 For US$30 Million 23
BioCryst Pharmaceuticals Inc, Key Competitors 24
BioCryst Pharmaceuticals Inc, Key Employees 25
BioCryst Pharmaceuticals Inc, Other Locations 26
BioCryst Pharmaceuticals Inc, Subsidiaries 26

★海外企業調査レポート[BioCryst Pharmaceuticals Inc (BCRX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Acuity Brands, Inc.:企業の戦略・SWOT・財務分析
    Acuity Brands, Inc. - Strategy, SWOT and Corporate Finance Report Summary Acuity Brands, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Nippon Soda Co Ltd (4041):企業の財務・戦略的SWOT分析
    Nippon Soda Co Ltd (4041) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Sodexo S.A.:戦略・SWOT・企業財務分析
    Sodexo S.A. - Strategy, SWOT and Corporate Finance Report Summary Sodexo S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Torchlight Energy Resources Inc (TRCH):企業の財務・戦略的SWOT分析
    Summary Torchlight Energy Resources Inc (Torchlight Energy), formerly Pole Perfect Studios Inc is an oil and gas exploration and production company. The company’s activities include acquisition, exploration and development of domestic oil fields. Its business process includes investment evaluation a …
  • Crescita Therapeutics Inc (CTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Crescita Therapeutics Inc (Crescita Therapeutics) is a commercial dermatology company that offers prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. The company’s products comprise Pliaglis, Alyria, Laboratoire Dr Renaud, Pro-Derm, Premi …
  • Acciona Energia SA:企業の戦略的SWOT分析
    Acciona Energia SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Stora Enso Oyj (STERV):企業の財務・戦略的SWOT分析
    Stora Enso Oyj (STERV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Grupo Catalana Occidente, S.A.:戦略・SWOT・企業財務分析
    Grupo Catalana Occidente, S.A. - Strategy, SWOT and Corporate Finance Report Summary Grupo Catalana Occidente, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Stena AB:企業の戦略的SWOT分析
    Stena AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Bavarian Nordic AS (BAVA):企業の財務・戦略的SWOT分析
    Bavarian Nordic AS (BAVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Spineology Inc:医療機器:M&Aディール及び事業提携情報
    Summary Spineology Inc (Spineology) is a medical device company that develops and designs spinal implants. The company offers products such as pedicular fixation system, interbody fusion system, deployable grafting system, amniotic fixation system, allografts, retractor system, liquid tissue matrix, …
  • Southwestern Electric Power Co:企業の戦略的SWOT分析
    Southwestern Electric Power Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Bajaj Auto Ltd:企業の戦略・SWOT・財務情報
    Bajaj Auto Ltd - Strategy, SWOT and Corporate Finance Report Summary Bajaj Auto Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • MiaSole Hi-Tech Corp:電力:M&Aディール及び事業提携情報
    Summary MiaSole Hi-Tech Corp (MiaSole) is an alternative energy company that manufactures, designs, develops, and markets thin-film photovoltaic solar cells and panels. The company's products include flexible solar cells, custom modules and SolarRide. It offers photovoltaic products for large-scale …
  • Omnicell Inc (OMCL):企業の財務・戦略的SWOT分析
    Omnicell Inc (OMCL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Rockwell Collins Inc:企業のM&A・事業提携・投資動向
    Rockwell Collins Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Rockwell Collins Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Access Bio Inc (950130):医療機器:M&Aディール及び事業提携情報
    Summary Access Bio Inc (Access Bio) is a medical device company that research, develops, manufactures and markets in-vitro diagnostics tests, biosensor, and molecular diagnostic products. The company provides in vitro diagnostic technology such as immunochemical, biochemical and molecular products. …
  • Nativis Inc-医療機器分野:企業M&A・提携分析
    Summary Nativis Inc (Nativis) is a clinical stage bio-electronics company. Its portfolio of pipeline candidates which are under development for various therapeutic areas include recurrent glioblastoma, brain metastisis, pain, rheumatoid arthritis, lung cancer and melanoma. The company’s lead product …
  • ShaMaran Petroleum Corp (SNM):石油・ガス:M&Aディール及び事業提携情報
    Summary ShaMaran Petroleum Corp (ShaMaran Petroleum), formerly Bayou Bend Petroleum Ltd is an independent oil and gas exploration and development company. The corporation explores, produces, and develops oil and gas assets. It holds interests and operates Atrush petroleum property located in Kurdist …
  • Birchcliff Energy Ltd (BIR)-石油・ガス分野:企業M&A・提携分析
    Summary Birchcliff Energy Ltd. (Birchcliff) is an intermediate oil and gas company that explores for, develops and produces natural gas, light oil and natural gas liquids. It operates in the Peace River Arch area to the northwest of Grande Prairie, Alberta. Peach River Arch region is one of the pote …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆